CO5160290A1 - DERIVATIVES OF REPLACED PHENOXYPHENYLOXAMIC ACID. - Google Patents

DERIVATIVES OF REPLACED PHENOXYPHENYLOXAMIC ACID.

Info

Publication number
CO5160290A1
CO5160290A1 CO00020338A CO00020338A CO5160290A1 CO 5160290 A1 CO5160290 A1 CO 5160290A1 CO 00020338 A CO00020338 A CO 00020338A CO 00020338 A CO00020338 A CO 00020338A CO 5160290 A1 CO5160290 A1 CO 5160290A1
Authority
CO
Colombia
Prior art keywords
optionally substituted
nr5r6
halogen
alkyl
hydrogen
Prior art date
Application number
CO00020338A
Other languages
Spanish (es)
Inventor
Jaana Kukkola Paivi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5160290A1 publication Critical patent/CO5160290A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

La presente invención se refiere a una composición de la fórmula :<EMI FILE="00020338_1" ID="1" IMF=JPEG >en donde:W es O, S, S (O) ó S(O)2X es -SR4, -S(O)R4, ó -S(O)2 R4, ó -S(O) NR5R6; ó X es-C (O) NR5R6 localizado en la posición 3´,4´, ó 5´;Y es O ó H2Z es hidrógeno, halógeno, hidroxilo, alcoxilo opcionalmente sustituido, aralcoxilo, acioxilo, o alcoxicarboniloxilo.R1 es hidroxilo, alcoxilo opcionalmente sustituido, ariloxilo, heteroariloxilo,Aralcoxilo, cicloalcoxilo, heteroaralcoxilo, ó -NR5R6;R2 es un hidrógeno, halógeno, o alquilo;R3 es halógeno o alquilo;R4 es alquilo opcionalmente sustituido, arilo, aralquilo, heteroalquilo, o heteroarilo.R5, R6, y R7 son independientemente hidrógeno, alquilo opcionalmente sustituido, cicloalquilo, arilo, aralquilo, heteroarilo, o heteroaralquilo; o R5 y R6 son combinados alquileno opcionalmente interrumpido por O, S, S(O), S(O)2, ó NR7, que junto con el átomo de nitrógeno con el que están unidos forman un anillo de 5 a 7 miembros;n representa 0 o un entero de 1 a 4;o una sal farmacéutica aceptable de el mismo.The present invention relates to a composition of the formula: <EMI FILE = "00020338_1" ID = "1" MFI = JPEG> where: W is O, S, S (O) or S (O) 2X is -SR4 , -S (O) R4, or -S (O) 2 R4, or -S (O) NR5R6; or X is-C (O) NR5R6 located in the 3´, 4´, or 5´ position; Y is O or H2Z is hydrogen, halogen, hydroxyl, optionally substituted alkoxy, aralkoxy, acioxy, or alkoxycarbonyloxy.R1 is hydroxyl, optionally substituted alkoxy, aryloxy, heteroaryloxy, Aralkoxy, cycloalkoxy, heteroaralkoxy, or -NR5R6; R2 is a hydrogen, halogen, or alkyl; R3 is halogen or alkyl; R4 is optionally substituted alkyl, aryl, aralkyl, heteroalkyl, or heteroaryl.R5 , R6, and R7 are independently hydrogen, optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or R5 and R6 are combined alkylene optionally interrupted by O, S, S (O), S (O) 2, or NR7, which together with the nitrogen atom with which they are attached form a 5 to 7 member ring; n represents 0 or an integer from 1 to 4; or an acceptable pharmaceutical salt thereof.

CO00020338A 1999-03-29 2000-03-22 DERIVATIVES OF REPLACED PHENOXYPHENYLOXAMIC ACID. CO5160290A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28010599A 1999-03-29 1999-03-29

Publications (1)

Publication Number Publication Date
CO5160290A1 true CO5160290A1 (en) 2002-05-30

Family

ID=23071698

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00020338A CO5160290A1 (en) 1999-03-29 2000-03-22 DERIVATIVES OF REPLACED PHENOXYPHENYLOXAMIC ACID.

Country Status (21)

Country Link
EP (1) EP1165502A1 (en)
JP (1) JP2002540189A (en)
KR (1) KR20010105394A (en)
CN (1) CN1345309A (en)
AU (1) AU4290800A (en)
BR (1) BR0009431A (en)
CA (1) CA2361016A1 (en)
CO (1) CO5160290A1 (en)
CZ (1) CZ20013449A3 (en)
HK (1) HK1042692A1 (en)
HU (1) HUP0200588A2 (en)
IL (1) IL144637A0 (en)
MX (1) MXPA01009843A (en)
NO (1) NO20014702L (en)
NZ (1) NZ514062A (en)
PE (1) PE20001587A1 (en)
PL (1) PL349355A1 (en)
RU (1) RU2001126579A (en)
SK (1) SK13812001A3 (en)
TR (1) TR200102225T2 (en)
WO (1) WO2000058279A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29889A (en) 1999-03-01 2001-10-18 Pfizer Prod Inc OXAMIC ACIDS AND ITS SUBSIDIARIES AS THIROID LIGHTS RECEPTORS
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
AU3092901A (en) 2000-02-17 2001-08-27 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
IL151376A0 (en) * 2000-03-31 2003-04-10 Pfizer Prod Inc Malonamic acids and derivatives thereof as thyroid receptor ligands
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
WO2001085670A1 (en) * 2000-05-12 2001-11-15 Kissei Pharmaceutical Co., Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and use thereof
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
DE10038007A1 (en) 2000-08-04 2002-02-14 Bayer Ag New amino and amido diphenyl ethers for drugs
DE10046029A1 (en) 2000-09-18 2002-03-28 Bayer Ag indazoles
WO2002032408A2 (en) * 2000-10-20 2002-04-25 Novartis Ag Combinations of a thyromimetic compound and a statin
JP2004517851A (en) 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト Indole derivatives as thyroid receptor ligands
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
DE10122443A1 (en) * 2001-05-09 2002-11-14 Bayer Ag Amido-diphenyl derivatives
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
ES2267945T3 (en) * 2001-05-31 2007-03-16 Pfizer Products Inc. MEDICAL USE OF TIROMIMETIC COMPOUNDS TO TREAT LOSS OF HAIR AND COMPOSITIONS.
DE10131462A1 (en) * 2001-06-29 2003-01-09 Bayer Ag Phenol derivatives
ATE313325T1 (en) 2001-09-26 2006-01-15 Pfizer Prod Inc INDOLCAROBOXYLIC ACID AS A THYROID RECEPTOR LIGAND
US6818766B2 (en) 2002-10-02 2004-11-16 Synthon Bv Process for making bicalutamide and intermediates thereof
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005105712A1 (en) * 2004-05-05 2005-11-10 Novo Nordisk A/S Sulfonamide derivatives
RU2416608C2 (en) 2004-08-06 2011-04-20 Оцука Фармасьютикал Ко., Лтд. Aromatic compound
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
CN101321529B (en) 2005-12-05 2012-09-05 大塚制药株式会社 Diaryl aether derivant as antineoplastic agent
UA95978C2 (en) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Stat3/5 activation inhibitor
WO2009133834A1 (en) * 2008-04-28 2009-11-05 塩野義製薬株式会社 Keto-amide derivative having inhibitory activity on endothelial lipase
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
CN104193699B (en) * 2014-08-14 2016-05-25 嘉兴特科罗生物科技有限公司 A kind of micromolecular compound and synthetic method and application
CN110198719A (en) 2016-11-21 2019-09-03 维京治疗公司 The method for treating glycogen storage disease
CA3064940A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
TW202115029A (en) * 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 Heterocyclic compound and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2108855T3 (en) * 1992-07-21 1998-01-01 Ciba Geigy Ag DERIVATIVES OF OXAMIC ACID AS HYPOCHOLESTEREMIC AGENTS.

Also Published As

Publication number Publication date
NO20014702D0 (en) 2001-09-27
NO20014702L (en) 2001-09-27
IL144637A0 (en) 2002-05-23
NZ514062A (en) 2001-09-28
TR200102225T2 (en) 2002-01-21
JP2002540189A (en) 2002-11-26
CZ20013449A3 (en) 2001-12-12
BR0009431A (en) 2002-01-08
RU2001126579A (en) 2004-02-27
WO2000058279A1 (en) 2000-10-05
CN1345309A (en) 2002-04-17
CA2361016A1 (en) 2000-10-05
AU4290800A (en) 2000-10-16
PL349355A1 (en) 2002-07-15
HK1042692A1 (en) 2002-08-23
EP1165502A1 (en) 2002-01-02
SK13812001A3 (en) 2002-04-04
MXPA01009843A (en) 2002-05-06
PE20001587A1 (en) 2001-01-31
HUP0200588A2 (en) 2002-07-29
KR20010105394A (en) 2001-11-28

Similar Documents

Publication Publication Date Title
CO5160290A1 (en) DERIVATIVES OF REPLACED PHENOXYPHENYLOXAMIC ACID.
CA2475432A1 (en) 2,4,6-triamino-1,3,5-triazine derivative
HUP0102404A2 (en) N-acyl cyclic amine derivatives, process for producing them and pharmaceutical compositions containing them
HUP0204587A2 (en) 6-position substituted indoline, production and use thereof as a medicament
CO5251463A1 (en) HETEROCICLICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUNDS
NZ503910A (en) Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
HUP0302167A2 (en) Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them
HUP0300329A2 (en) Malonamic acids and derivatives and use thereof as thyroid receptor ligands and for preparation of pharmaceutical compositions containing them
CA2355075A1 (en) Heteroaryl-cyclic acetals
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
AU4555800A (en) Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
MY113427A (en) Anti-neurodegeneratively active 10-aminoaliphatyl- dibenz [b,f] oxepines
EA200100059A2 (en) New benzenesulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them
JO2307B1 (en) Pyrimidine derivatives
HUP9801057A2 (en) Pyridyl-thiazoles and their use to protect plants against infections by micro-organisms
TW350838B (en) Quinoline derivatives
EP0335979A4 (en) Thienopyrimidine derivatives
CO5140091A1 (en) DERIVATIVES OF PIPERIDINE AND PIPERAZINE, ITS PREPARATION, ITS USE AS PHARMACEUTICAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
YU34499A (en) 5-aroylnaphthalene derivatives
EP0552489A3 (en)
EP1864977A4 (en) Novel cyclic compound having pyrimidinylalkylthio group
ATE99326T1 (en) N-PHENYL-N-ALKOXYCARBONYLALKYL-GLYCINAMIDES, THEIR PREPARATION AND MEDICATIONS CONTAINING THEM.
EA200100635A1 (en) DERIVATIVES OF THIOMOCHEVIA AS HERPES VIRUS INHIBITORS
ES2174077T3 (en) ANTI-CHEMICAL HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS.
HUP9902088A2 (en) Substituted 1,3-benzodioxole derivatives, pharmaceutical compositions containing them and process for their preparation